Genetic evidence has been widely observed as a proxy for success in drug clinical trials, due to an increased understanding of the causal mechanism between drug target and disease. The seminar will focus on how various streams of genetics data are ingested, processed, and combined into the overall Open Targets evidence framework, and also how researchers may utilise this resource with their own data.